Allogeneic Therapeutics Announce – GuruFocus.com

  • Cells derived from healthy, younger donors were abundant and had greater fitness and cancer-killing potential than cells derived from cancer patients
  • The results underscore the potential of allogeneic CAR-T products to improve patient outcomes

SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer , will today present preclinical results evaluating the properties and function of donor-derived allogeneic CAR-T cells. The data showed that cells from a variety of younger donors had improved and better properties in vitro Anti-tumor activity compared to cells from older donors. The study also showed that cells from patients with certain cancers generally performed suboptimally based on functional assays and often could not be used to develop viable CAR-T therapies. The results will be presented during an oral session at the 2022 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting at 10:45 a.m. ET.

“These results reinforce the benefits and properties of allogeneic CAR-T cells derived from healthy donors and the potential of AlloCAR-Ts to improve patient outcomes,” said Rafael G. Amado, MD, Executive Vice President of Research and Development and Chief Medical Officer at Allogen. “Cells derived from healthy, younger donors were abundant, with greater fitness and cancer-killing potential, and have the potential to eliminate the risk of manufacturing defects seen with autologous CART therapies.”

The study evaluated the properties and performance of CAR-T cells derived from healthy donors aged 19 to 62 and compared the healthy donor cells to those derived from cancer patients. Based on the analysis, CAR T cells produced by younger donors had stronger and better T cell phenotypes in vitro Anti-tumor activity cytotoxicity compared to older donors. The expression of specific exhaustion and activation markers also correlated with increased donor age and in vitro Antitumor activity decreased with donor age. Regardless of age, CAR-T cells derived from healthy donors performed better and had a lower production failure rate compared to those derived from cancer patients.

Generation of allogeneic CAR-T cells from healthy donors reduces product variability; reduces the risk of manufacturing defects; and allows treatment within days, eliminating the need for bridging chemotherapy. This study provides additional evidence that younger, healthy donors can improve product performance and efficacy compared to older donors.
Allogene is currently conducting four clinical programs evaluating the potential of AlloCAR T product candidates for the treatment of relapsed/refractory (R/R) large B-cell lymphoma, multiple RR myeloma and advanced renal cell carcinoma.

About allogeneic therapeutics
Headquartered in South San Francisco, Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) products for cancer. Led by a management team with extensive experience in cell therapy, Allogene is developing a pipeline of “commercially available” CAR-T cell candidates with the goal of delivering readily available on-demand cell therapy more reliably and at scale to more patients. For more information, visit www.allogen.com and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note Regarding Allogeneic Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “estimate”, “anticipate”, “expect”, “plan”, “intend”, “may”, “might”, “might”, “will”, “should” or other words conveying uncertainty about future events or results to identify these forward-looking statements. Forward-looking statements include statements of intent, belief, projections, prospects, analysis or current expectations regarding, among other things: the potential for allogeneic CAR-T cells derived from healthy, younger donors to be more abundant, with greater fitness and cancer-killing potential than autologous ones CAR-T cells; the potential of allogeneic CAR-T cells to improve patient outcomes; the ability to advance clinical trials of AlloCAR T™ product candidates; and the ability to manufacture AlloCAR T™ products. Various factors could cause Allogene’s expectations to differ from actual results, as discussed more fully in Allogene’s filings with the SEC, including but not limited to its Form 10-Q for the quarter ended March 31, 2022. Any forward-looking statements made in this press release speak only as of the date of this press release. Allogene undertakes no obligation to update any forward-looking statements after the date of this press release, whether as a result of new information, future events or otherwise.

AlloCAR T is a trademark of Allogene Therapeutics, Inc.

Allogeneic media/investor contact:
Christine Cassian
Chief Communications Officer
(714) 552-0326
[email protected]

Allogene-Therapeutics-Inc-.png

Comments are closed.